Publications from the Nanotechnology Characterization Lab
Recent Publications
Evaluation of nonmodified wireframe DNA origami for acute toxicity and biodistribution in mice.
Wamhoff EC, Knappe GA, Burds AA, Du RR, Neun BW, Difilippantonio S, Sanders C, Edmondson EF, Matta JL, Dobrovolskaia MA, Bathe M.
ACS Appl Bio Mater. 2023. [PubMed Abstract]
Plasma stability and plasma metabolite concentration-time profiles of oligo(lactic acid)(8)-paclitaxel prodrug loaded polymeric micelles.
Repp L, Skoczen SL, Rasoulianboroujeni M, Stern ST, Kwon GS.
AAPS J. 2023; 25(3): 39. [PubMed Abstract]
Target-specific nanoparticle polyplex down-regulates mutant Kras to prevent pancreatic carcinogenesis and halt tumor progression.
Smith JP, Chen W, Shivapurkar N, Gerber M, Tucker RD, Kallakury B, Dasa SSK, Kularatne RN, Stern ST.
Int J Mol Sci. 2023; 24(1): 752. [PubMed Abstract]
Nanocomplexes of doxorubicin and DNA fragments for efficient and safe cancer chemotherapy.
Mohammad SN, Choi YS, Chung JY, Cedrone E, Neun BW, Dobrovolskaia MA, Yang X, Guo W, Chew YC, Kim J, Baek S, Kim IS, Fruman DA, Kwon YJ.
J Control Release. 2023; 354: 91-108. [PubMed Abstract]
Innate immune stimulation using 3D wireframe DNA origami.
Du RR, Cedrone E, Romanov A, Falkovich R, Dobrovolskaia MA, Bathe M.
ACS Nano. 2022; 16(12): 20340-20352. [PubMed Abstract]
Trends and patterns in cancer nanotechnology research: A survey of NCI's caNanoLab and Nanotechnology Characterization Laboratory.
Ke W, Crist RM, Clogston JD, Stern ST, Dobrovolskaia MA, Grodzinski P, and Jensen MA.
Adv Drug Deliv Rev. 2022; 114591. [PubMed Abstract]
Expanding structural space for immunomodulatory nucleic acid nanoparticles (Nanps) via spatial arrangement of their therapeutic moieties.
Chandler M, Rolband L, Johnson MB, Shi D, Avila YI, Cedrone E, Beasock D, Danai L, Stassenko E, Krueger JK, Jiang J, Lee JS, Dobrovolskaia MA, Afonin KA.
Adv Funct Mater. 2022; 32(43). [PubMed Abstract]
Lessons learned from immunological characterization of nanomaterials at the Nanotechnology Characterization Laboratory.
Dobrovolskaia MA.
Front Immunol. 2022; 13: 984252. [PubMed Abstract]
Artificial immune cell, AI-cell, a new tool to predict interferon production by peripheral blood monocytes in response to nucleic acid nanoparticles.
Chandler M, Jain S, Halman J, Hong E, Dobrovolskaia MA, Zakharov AV, Afonin KA.
Small. 2022, e2204941. [PubMed Abstract]
Cancer nanomedicine.
Bhatia SN, Chen X, Dobrovolskaia MA, Lammers T.
Nature Reviews Cancer. 2022; 22(10): 550-556. [PubMed Abstract]
Locking and unlocking thrombin function using immunoquiescent nucleic acid nanoparticles with regulated retention in vivo.
Ke W, Chandler M, Cedrone E, Saito RF, Rangel MC, de Souza Junqueira M, Wang J, Shi D, Truong N, Richardson M, Rolband LA, Dreau D, Bedocs P, Chammas R, Dokholyan NV, Dobrovolskaia MA, Afonin KA.
Nano Letters. 2022; 22(14): 5961-5972. [PubMed Abstract]
The future of tissue-targeted lipid nanoparticle-mediated nucleic acid delivery.
Kularatne RN, Crist RM, Stern ST.
Pharmaceuticals. 2022; 15(7): 897. [PubMed Abstract]
Immunophenotyping: analytical approaches and role in preclinical development of nanomedicines.
Newton HS, Dobrovolskaia MA.
Adv Drug Deliv Rev. 2022; 185: 114281. [PubMed Abstract]
Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines.
Szebeni J, Storm G, Ljubimova JY, Castells M, Phillips EJ, Turjeman K, Barenholz Y, Crommelin DJA, Dobrovolskaia MA.
Nat Nanotechnol. 2022; 17(4): 337-346. [PubMed Abstract]
For a more comprehensive list of NCL publications, visit our Web of Science bibliography page.